In a large analysis using the California Cancer Registry (CCR), our group described that delays in chemotherapy administration affect survival outcomes with a particular detriment among patients with stage III disease or HER2‐positive or triple negative BC (TNBC).4 The gene discussed is ERBB2; the disease is breast cancer.